Amalgamated Bank Sells 5,305 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Amalgamated Bank decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 87,094 shares of the medical equipment provider’s stock after selling 5,305 shares during the quarter. Amalgamated Bank’s holdings in Intuitive Surgical were worth $29,382,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brookstone Capital Management grew its holdings in shares of Intuitive Surgical by 277.7% during the 3rd quarter. Brookstone Capital Management now owns 7,259 shares of the medical equipment provider’s stock worth $1,985,000 after purchasing an additional 5,337 shares in the last quarter. Commonwealth Equity Services LLC increased its position in Intuitive Surgical by 10.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 61,148 shares of the medical equipment provider’s stock valued at $17,873,000 after acquiring an additional 6,018 shares during the period. Vicus Capital bought a new position in shares of Intuitive Surgical during the third quarter valued at $263,000. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Intuitive Surgical by 15.1% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 27,295 shares of the medical equipment provider’s stock worth $7,978,000 after purchasing an additional 3,589 shares during the period. Finally, Raymond James & Associates grew its position in shares of Intuitive Surgical by 31.1% in the 3rd quarter. Raymond James & Associates now owns 330,983 shares of the medical equipment provider’s stock valued at $96,743,000 after buying an additional 78,457 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Stock Up 1.6 %

Intuitive Surgical stock traded up $5.95 during midday trading on Thursday, hitting $377.65. 1,001,453 shares of the stock were exchanged, compared to its average volume of 1,629,199. The stock has a market capitalization of $133.96 billion, a price-to-earnings ratio of 67.09, a price-to-earnings-growth ratio of 4.79 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The business’s 50-day moving average price is $385.79 and its 200-day moving average price is $348.35.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the previous year, the company earned $1.00 earnings per share. The company’s quarterly revenue was up 11.5% on a year-over-year basis. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of recent analyst reports. Barclays lifted their price objective on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Piper Sandler lifted their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. Mizuho raised their target price on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Stifel Nicolaus boosted their price target on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $396.17.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Myriam Curet sold 481 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $386.09, for a total transaction of $185,709.29. Following the sale, the executive vice president now directly owns 298 shares in the company, valued at approximately $115,054.82. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 226,928 shares of company stock valued at $87,833,828. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.